These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 526925)

  • 41. Determinants of Ara-C action: biochemical consideration.
    Rustum YM; Slocum HK; Li ZR
    Prog Clin Biol Res; 1983; 132E():107-20. PubMed ID: 6689076
    [No Abstract]   [Full Text] [Related]  

  • 42. Single versus combination chemotherapy of L1210 leukemia.
    Koza I; Balázová E; Ujházy V
    Neoplasma; 1980; 27(6):691-6. PubMed ID: 7254424
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. X.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1972 Nov; 3(1):1-69. PubMed ID: 4660732
    [No Abstract]   [Full Text] [Related]  

  • 44. Toxicity and antitumor activity of cis-bis-cyclopentenecarboxylato-1,2-diaminocyclohexane platinum(II) encapsulated in multilamellar vesicles.
    Perez-Soler R; Khokhar AR; Hacker MP; Lopez-Berestein G
    Cancer Res; 1986 Dec; 46(12 Pt 1):6269-73. PubMed ID: 3779646
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
    Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
    Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Distribution and metabolism of lipsome-encapsulated and free 1-beta-D-arabinofuranosylcytosine (Ara-C) in dog and mouse tissues.
    Ellens H; Rustum Y; Mayhew E; Ledesma E
    J Pharmacol Exp Ther; 1982 Aug; 222(2):324-30. PubMed ID: 7097552
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency.
    Venditti JM; Baratta MC; Greenberg NH; Abbott BJ; Kline I
    Cancer Chemother Rep; 1972 Aug; 56(4):483-92. PubMed ID: 5081591
    [No Abstract]   [Full Text] [Related]  

  • 48. Characterization of liposomes prepared using a microemulsifier.
    Mayhew E; Lazo R; Vail WJ; King J; Green AM
    Biochim Biophys Acta; 1984 Aug; 775(2):169-74. PubMed ID: 6466665
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Development of leukemia L-1210 after treatment with the methionine synthetase inhibitor quinoline dibromide].
    Kudriavtsev IA; Paramonova TD; Golenko OD; Miasishcheva NV
    Probl Gematol Pereliv Krovi; 1982 Jul; 27(7):27-31. PubMed ID: 7122454
    [No Abstract]   [Full Text] [Related]  

  • 50. [Liposomes as carriers of lipophilic cytosine arabinoside and fluorodeoxyuridine derivatives. Their cytostatic effect and possibilities of tumor cell specific therapy].
    Schwendener RA; Schott H; Hartmann HR; Supersaxo A; Rubas W; Hengartner H
    Onkologie; 1987 Aug; 10(4):232-9. PubMed ID: 2959889
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antitumor effect of 1-beta-D-arabinofuranosylcytosine 5'-adamantoate (NSC 117614) in L1210 leukemic mice.
    Neil GL; Wiley PF; Manak RC; Moxley TE
    Cancer Res; 1970 Apr; 30(4):1047-54. PubMed ID: 5504347
    [No Abstract]   [Full Text] [Related]  

  • 52. A computer model for tumor growth and chemotherapy, and its application to L1210 leukemia treated with cytosine arabinoside (NSC-63878).
    Shackney SE
    Cancer Chemother Rep; 1970 Dec; 54(6):399-429. PubMed ID: 5527022
    [No Abstract]   [Full Text] [Related]  

  • 53. Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine.
    Hong F; Mayhew E
    Cancer Res; 1989 Sep; 49(18):5097-102. PubMed ID: 2766280
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
    Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR
    Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of dose interval on the survival of L1210 leukemic mice treated with DNA synthesis inhibitors.
    Neil GL; Homan ER
    Cancer Res; 1973 Apr; 33(4):895-901. PubMed ID: 4696483
    [No Abstract]   [Full Text] [Related]  

  • 56. Multivesicular liposomes containing cytarabine entrapped in the presence of hydrochloric acid for intracavitary chemotherapy.
    Kim S; Howell SB
    Cancer Treat Rep; 1987; 71(7-8):705-11. PubMed ID: 3607782
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside.
    Kessel D; Hall TC; Wodinsky I
    Science; 1967 Jun; 156(3779):1240-1. PubMed ID: 6025544
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J; Lee A; Lu Y; Lee RJ
    Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dose-related synergism of cytosine arabinoside and methotrexate against murine leukemia L1210.
    Avery TL; Roberts D
    Eur J Cancer (1965); 1974 Jul; 10(7):425-9. PubMed ID: 4457345
    [No Abstract]   [Full Text] [Related]  

  • 60. Metabolic fate of O2,2'-cyclocytidine.
    Ho DH
    Drug Metab Dispos; 1973; 1(6):752-5. PubMed ID: 4156296
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.